FDA allows IND application for Athenex PT01

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has allowed Athenex Inc.’s Investigational New Drug application for the clinical investigation of PT01 (Pegtomarginase) for the treatment of patients with advanced malignancies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login